Choong Ang Vaccine Laboratory Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 26, 2022 at 07:38 am
Share
Choong Ang Vaccine Laboratory Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 0.00006 million compared to negative sales of KRW 0.00017 million a year ago. Net income was KRW 1,508.05 million compared to KRW 2,131.31 million a year ago. Basic earnings per share from continuing operations was KRW 155 compared to KRW 216 a year ago. Diluted earnings per share from continuing operations was KRW 155 compared to KRW 216 a year ago. Basic earnings per share was KRW 155 compared to KRW 216 a year ago.
For the six months, sales was KRW 0.00034 million compared to negative sales of KRW 0.00026 million a year ago. Net income was KRW 3,757.35 million compared to KRW 3,772.59 million a year ago. Basic earnings per share from continuing operations was KRW 385 compared to KRW 383 a year ago. Diluted earnings per share from continuing operations was KRW 385 compared to KRW 383 a year ago. Basic earnings per share was KRW 385 compared to KRW 383 a year ago.
Choong Ang Vaccine Laboratory Co., Ltd. is a Korea-based company mainly engaged in the manufacturing and marketing of veterinary vaccines. The Company provides veterinary vaccines for fowl, dogs, pigs, cattle, rabbits, cats, fishes and others under the brand name SuiShot, PoulShot, Canishot, BoviShot, FeliShot, RabbiShot and AquaShot. The Company also provides diagnosis services, and distributes other veterinary drugs, such as antibiotics, anthelmintics, disinfectants and feed additives. The Company distributes its products within domestic market and to overseas markets.
CHOONG ANG VACCINE LABORATORY CO., LTD. 
